Nektar Therapeutics (NKTR) Finished Goods (2010 - 2024)

Nektar Therapeutics' Finished Goods history runs 13 years deep, the most recent figure standing at $2.2 million for Q2 2024.

• On a quarterly basis, Finished Goods changed N/A year-over-year to $2.2 million in Q2 2024; TTM through Jun 2024 was $2.2 million, a N/A change from a year earlier, with the FY2023 full-year figure at $1.4 million, down 76.86% from the prior year.
• Finished Goods retreated to $2.2 million in Q2 2024 per NKTR's latest filing, from $4.3 million in the prior quarter.
• Across five years, Finished Goods topped out at $5.9 million in Q4 2022 and bottomed at $921000.0 in Q3 2023.
• The 3-year median for Finished Goods is $2.2 million (2024), against an average of $2.9 million.
• Biggest YoY gain for Finished Goods was 76.86% in 2023; the steepest drop was 76.86% in 2023.
• Year by year, Finished Goods stood at $5.9 million in 2022, then plunged by 76.86% to $1.4 million in 2023, then jumped by 58.53% to $2.2 million in 2024.
• Per Business Quant, the three latest NKTR Finished Goods figures stand at $2.2 million (Q2 2024), $4.3 million (Q1 2024), and $1.4 million (Q4 2023).